Abstract
Background Microglial activation occurs early in Alzheimer’s disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. Therefore, it is critical to investigate at which AD stages microglial activation could be protective or detrimental to evaluate microglia as a treatment target. To address this, we used CSF sTREM2 (i.e. Triggering receptor expressed on myeloid cells 2) to investigate disease stage-dependent drivers of microglial activation and to determine downstream consequences on AD biomarker progression.
Methods We included 402 cognitively normal and mild cognitively impaired patients with CSF sTREM2 assessments. To assess AD severity, we included measures of earliest beta-amyloid (i.e. Aβ) in CSF (i.e. Aβ1-42) and late-stage fibrillary Aβ pathology (i.e. amyloid-PET centiloid), as well as p-tau181 and FDG-PET for assessing downstream changes in tau and cerebral glucose metabolism. To determine disease stage, we stratified participants according to earliest Aβ abnormalities (i.e. Aβ CSF+/PET−; early Aβ-accumulators, n=70) or fully developed fibrillary Aβ pathology (i.e. Aβ CSF+/PET+; late Aβ-accumulators, n=201) plus 131 healthy controls (i.e. Aβ CSF−/PET−).
Results In early Aβ-accumulators, higher centiloid was associated with cross-sectional/longitudinal sTREM2 and p-tau increases, suggesting reactive microglial and p-tau increases in response to earliest Aβ fibrillization. Further, higher sTREM2 mediated the association between centiloid and cross-sectional/longitudinal p-tau increases and higher sTREM2 was associated with FDG-PET hypermetabolism in line with previous findings of increased glucose consumption of activated microglia. In late Aβ-accumulators, we found no association between centiloid and sTREM2 but a cross-sectional association between higher sTREM2, higher p-tau and glucose hypometabolism, suggesting that sTREM2 parallels tau and neurodegeneration rather than Aβ once fully developed Aβ pathology is present.
Conclusions Our findings suggest that sTREM2-related microglial activation occurs in response to earliest Aβ fibrillization, manifests in inflammatory glucose hypermetabolism and may facilitate subsequent p-tau increases in earliest AD, while previous reports of protective sTREM2 effects may occur in later AD stages.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by grants from the LMU (FoeFoLe, 1032, awarded to NF; FoeFoLe, 1119, awarded to DB), the Hertie foundation for clinical neurosciences (awarded to NF), the SyNergy excellence cluster (EXC 2145/ID 390857198) and the German Research Foundation (DFG, INST 409/193-1 FUGG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained by the ADNI investigators from the local ethical committees of all involved sites. The study was conducted in accordance with the Declaration of Helsinki and all study participants provided written informed consent. All work complied with ethical regulations for work with human participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
† Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Data Availability
All data used in this manuscript are publicly available from the ADNI database (adni.loni.usc.edu) upon registration and compliance with the data use agreement. The data that support the findings of this study are available on reasonable request from the corresponding author.
Abbreviations
- Aβ
- amyloid-beta
- AD
- Alzheimer’s disease
- ADNI
- Alzheimer’s Disease Neuroimaging Initiative
- CN
- cognitively normal
- CSF
- cerebrospinal fluid
- FDG
- F-flurodeoxyglucose
- MCI
- mild cognitively impaired
- MMSE
- Mini Mental State Examination
- ROI
- region of interest
- sTREM2
- soluble Triggering Receptor Expressed on Myeloid Cell 2
- SUVR
- standardized uptake value ratio